In human prostate cancer cells (DU145 and PC3), silibinin reduced gene expression levels of EZH2 by increasing H3K27me3 levels, decreased histone deacetylases 1–2 (HDACs1-2) expression levels, and increased total DNMTs activity (173). The gene discussed is HDAC1; the disease is prostate cancer.